These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 26026214)

  • 1. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Di Martino M; Versacci P; Andreoli G; Silvestri LM; Chiesa C
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):734-41. PubMed ID: 26026214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial.
    Nobili V; Bedogni G; Alisi A; Pietrobattista A; Risé P; Galli C; Agostoni C
    Arch Dis Child; 2011 Apr; 96(4):350-3. PubMed ID: 21233083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children.
    Nobili V; Alisi A; Della Corte C; Risé P; Galli C; Agostoni C; Bedogni G
    Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1066-70. PubMed ID: 23220074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic fat and β-cell function in overweight/obese children with nonalcoholic fatty liver disease.
    Pacifico L; Di Martino M; Anania C; Andreoli GM; Bezzi M; Catalano C; Chiesa C
    World J Gastroenterol; 2015 Apr; 21(15):4688-95. PubMed ID: 25914480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease.
    Granér M; Nyman K; Siren R; Pentikäinen MO; Lundbom J; Hakkarainen A; Lauerma K; Lundbom N; Nieminen MS; Taskinen MR
    Circ Cardiovasc Imaging; 2015 Jan; 8(1):. PubMed ID: 25550397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of hepatic steatosis to adipose tissue distribution in pediatric nonalcoholic fatty liver disease.
    Fishbein MH; Mogren C; Gleason T; Stevens WR
    J Pediatr Gastroenterol Nutr; 2006 Jan; 42(1):83-8. PubMed ID: 16385259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docosahexaenoic acid prevents trans-10, cis-12-conjugated linoleic acid-induced nonalcoholic fatty liver disease in mice by altering expression of hepatic genes regulating fatty acid synthesis and oxidation.
    Fedor DM; Adkins Y; Mackey BE; Kelley DS
    Metab Syndr Relat Disord; 2012 Jun; 10(3):175-80. PubMed ID: 22242926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial.
    Zöhrer E; Alisi A; Jahnel J; Mosca A; Della Corte C; Crudele A; Fauler G; Nobili V
    Appl Physiol Nutr Metab; 2017 Sep; 42(9):948-954. PubMed ID: 28511023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial.
    Janczyk W; Lebensztejn D; Wierzbicka-Rucińska A; Mazur A; Neuhoff-Murawska J; Matusik P; Socha P
    J Pediatr; 2015 Jun; 166(6):1358-63.e1-3. PubMed ID: 25771388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial.
    Parker HM; Cohn JS; O'Connor HT; Garg ML; Caterson ID; George J; Johnson NA
    Nutrients; 2019 Feb; 11(2):. PubMed ID: 30813440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial.
    Della Corte C; Carpino G; De Vito R; De Stefanis C; Alisi A; Cianfarani S; Overi D; Mosca A; Stronati L; Cucchiara S; Raponi M; Gaudio E; Byrne CD; Nobili V
    PLoS One; 2016; 11(12):e0168216. PubMed ID: 27977757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.
    Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Hodson L; Moyses HE; Calder PC; Byrne CD;
    Hepatology; 2014 Oct; 60(4):1211-21. PubMed ID: 25043514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of epicardial fat and alanine aminotransferase in subjects with increased visceral fat.
    Iacobellis G; Pellicelli AM; Grisorio B; Barbarini G; Leonetti F; Sharma AM; Barbaro G
    Obesity (Silver Spring); 2008 Jan; 16(1):179-83. PubMed ID: 18223632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
    Bhatia L; Scorletti E; Curzen N; Clough GF; Calder PC; Byrne CD
    Atherosclerosis; 2016 Mar; 246():13-20. PubMed ID: 26748347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study.
    Oscarsson J; Önnerhag K; Risérus U; Sundén M; Johansson L; Jansson PA; Moris L; Nilsson PM; Eriksson JW; Lind L
    J Clin Lipidol; 2018; 12(6):1390-1403.e4. PubMed ID: 30197273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Marandola L; Romaggioli S; Bascetta S; Chiesa C
    World J Gastroenterol; 2014 Dec; 20(45):17107-14. PubMed ID: 25493023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
    Alkassabany YM; Farghaly AG; El-Ghitany EM
    Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.